IL1B and type 1 diabetes mellitus: Using canakinumab, a human anti-IL-1β monoclonal antibody, a randomized controlled trial of an IL-1β blockade was carried out to investigate a possible improvement in the beta-cell function of patients with new-onset T1D [178].